Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers

Bushra Shariff; Reagan M. Barnett; Farshid Dayyani; Steven B. Maron; Rory Mcgriskin; Samuel J. Klempner; Elifnur Yay Donderici; Nicole Zhang; Jude Masannat; Leylah Drusbosky; Rutika Mehta

doi:10.1093/oncolo/oyae061

June 21, 2024The OncologistOpen Access

Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers

View Full Paper

Ask AI

Bookmark

Share

Abstract

In addition to the existing biomarkers HER2 and PD-L1, FGFR2b has become an area of interest for the development of new targeted-based treatment. Given that clinical evaluation of FGFR2 targeted therapy is underway, we sought to elucidate the genomic landscape of FGFR2amp in gastroesophageal cancer (GEC) using a circulating tumor DNA (ctDNA) platform.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shariff et al. (2024) studied this question.

synapsesocial.com/papers/68e63d21b6db6435875cf525 https://doi.org/10.1093/oncolo/oyae061

View Full Paper

Ask AI

Bookmark

Share

Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers

Abstract

Discussion

Cite This Study

Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from The Oncologist

Keep reading

More related papers

More from The Oncologist